Multitarget Therapeutic Strategies for Chagas Disease: Natural Compounds, Antimicrobial Peptides, and Cell-Based Immunomodulation
Preprint
- 14 May 2026
- preprint
- Published by MDPI AG in Preprints.org
Abstract
Chagas disease, caused by Trypanosoma cruzi, remains a major public health problem in Latin America and an emerging global health concern due to population mobility. Alt-hough benznidazole and nifurtimox remain the only approved antiparasitic drugs, their limited efficacy in chronic infection, prolonged treatment regimens, frequent adverse ef-fects, and variable activity across parasite strains highlight the need for new therapeutic strategies. In addition, the pathogenesis of chronic Chagas disease is driven not only by parasite persistence but also by immune-mediated tissue damage, particularly in chronic Chagas cardiomyopathy. In this review, we examine emerging therapeutic approaches that extend beyond conventional trypanocidal chemotherapy, with emphasis on plant-derived extracts, essential oils, antimicrobial peptides, and cell-based immuno-modulatory strategies. Plant compounds and essential oils have shown antiparasitic ac-tivity through mechanisms including oxidative stress induction, membrane disruption, interference with sterol biosynthesis, and mitochondrial dysfunction, while some extracts also modulate host immune responses. Antimicrobial peptides display dual potential by directly damaging parasite membranes and organelles or by reshaping infec-tion-associated inflammatory responses. In parallel, cell-based therapies such as mesen-chymal stromal cells, tolerogenic dendritic cells, and bone marrow-derived cells have demonstrated promising cardioprotective and immunoregulatory effects in experimental chronic Chagas disease. Collectively, these approaches support a multitarget therapeutic framework in which parasite-directed and host-directed interventions may complement each other. Further mechanistic studies, standardization, and translational validation will be essential to advance these candidates toward clinically useful therapies for Chagas disease.Keywords
All Related Versions
- Version 1, 2026-05-14, Preprints
- Published version: Infectious Disease Reports, 18 (4), 65.
This publication has 79 references indexed in Scilit:
- Expression Analysis of Thirteen Genes in Response to Nifurtimox and Benznidazole in Mexican Isolates of Trypanosoma cruzi by Digital PCRActa Parasitologica, 2025
- Microalgae extracts modulates the immune response in Trypanosoma cruzi-infected human cellsCytokine, 2024
- Advances in the treatment of Chagas disease: Promising new drugs, plants and targetsBiomedicine & Pharmacotherapy, 2021
- Antiprotozoal alkaloid principles of the plant family AmaryllidaceaeBioorganic & Medicinal Chemistry Letters, 2019
- Current advances in drug discovery for Chagas diseaseEuropean Journal of Medicinal Chemistry, 2018
- Vasoactive intestinal peptide reduces the inflammatory profile in mice infected with Trypanosoma cruziExperimental Parasitology, 2015
- Anti-Trypanosoma cruzi activity of 10 medicinal plants used in northeast MexicoActa Tropica, 2014
- Toxic and therapeutic effects of Nifurtimox and Benznidazol on Trypanosoma cruzi ex vivo infection of human placental chorionic villi explantsActa Tropica, 2014
- Trypanosoma cruzi: Activity of essential oils from Achillea millefolium L., Syzygium aromaticum L. and Ocimum basilicum L. on epimastigotes and trypomastigotesExperimental Parasitology, 2007
- Effect of oregano (Origanum vulgare L.) and thyme (Thymus vulgaris L.) essential oils on Trypanosoma cruzi (Protozoa: Kinetoplastida) growth and ultrastructureParasitology Research, 2006